PCAS - Press release of 10 December 2019
10 Décembre 2019 - 06:00PM
PCAS - Press release of 10 December 2019
Massy, December 10, 2019
The PCAS Board of Directors held a meeting on
December 9, 2019. During the meeting, members reviewed the Group's
business forecasts and projected results for 2019.
The Group's results for 2019 will mainly be
affected by the operational difficulties experienced in the
Pharmaceutical Synthesis activity and, to a lesser extent, the
slowdown in our lubricants activities towards the end of the year.
Therefore, the operating result in the Pharmaceutical Synthesis
activity and the net result of PCAS Group in 2019 will be
significantly lower than the performance achieved during the
previous financial year. For the record, the Group’s net income
will include the costs of reorganizing the Longjumeau site
announced at the end of 2018, which were recorded in the 2019
half-yearly financial statements.
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 9% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €206.7 million in 2018 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
- PCAS - communiqué du 10 décembre 2019_en-US
PCAS (EU:PCA)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
PCAS (EU:PCA)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024